NovaBridge Biosciences is a clinical-stage biotech developing biologic therapies for cancer and retinal disease, with no approved products and no product revenue today. Its lead asset, givastomig, is a bispecific antibody targeting CLDN18.2 and 4-1BB, being studied in first-line HER2-negative gastric and gastroesophageal cancer in combination with nivolumab and chemotherapy. NovaBridge co-owns givastomig 50/50 with ABL Bio for rights outside Greater China and South Korea. The second core program, VIS-101, is a VEGF-A × ANG-2 bispecific biologic for wet AMD and diabetic macular edema, held through subsidiary Visara and in Phase 2 development, with a Phase 3 study targeted for the first half of 2027. NovaBridge also holds two earlier-stage immuno-oncology assets — uliledlimab (CD73 antibody, development paused pending Phase 2 data) and ragistomig (PD-L1 × 4-1BB bispecific, co-developed with ABL Bio in a passive role). NovaBridge funds itself through equity raises and partnerships. Its business model aims to either license assets to larger pharma companies for upfront payments, milestones, and royalties, or achieve regulatory approval and commercialize directly. NovaBridge's "platform company" structure, adopted in late 2025, spins individual programs into subsidiaries to attract targeted outside investment and share clinical risk, as illustrated by the Visara structure for VIS-101. Key cost drivers are clinical trial expenses, R&D headcount, and external manufacturing through CDMOs.